All In Biotech

Drug Trial Radar · NCT03036124

Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure

Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure With Reduced Ejection Fraction

Last checked: Nov 19, 2026Latest source record: Sep 1, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 4,744 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,744

Actual

Start

Feb 8, 2017

Primary completion

Jul 17, 2019

Study completion Jul 17, 2019

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jan 30, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction

Conditions

  • Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)

Interventions

  • DapagliflozinDrug

    10 mg or 5 mg tablets given once daily, per oral use.

  • PlaceboDrug

    Placebo matching dapagliflozin 10 mg or 5 mg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure.Time frame: Up to 27.8 months.

Locations

419 sites in 20 countries. Site status is shown where the registry gives one.

  • Research Site

    Fairhope, Alabama

  • Research Site

    Mobile, Alabama

  • Research Site

    Sheffield, Alabama

  • Research Site

    Bakersfield, California

  • Research Site

    Beverly Hills, California

  • Research Site

    Los Angeles, California

  • Research Site

    Palm Springs, California

  • Research Site

    Stockton, California

  • Research Site

    Torrance, California

  • Research Site

    Vista, California

  • Research Site

    Wilmington, Delaware

  • Research Site

    Boynton Beach, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Lake Worth, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Naples, Florida

  • Research Site

    New Smyrna Beach, Florida

  • Research Site

    Pembroke Pines, Florida

  • Research Site

    Port Charlotte, Florida

  • Research Site

    Saint Augustine, Florida

  • Research Site

    Wellington, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Cumming, Georgia

  • Research Site

    Tucker, Georgia

  • Research Site

    Hazel Crest, Illinois

  • Research Site

    Jerseyville, Illinois

  • Research Site

    Peoria, Illinois

  • Research Site

    Louisville, Kentucky

  • Research Site

    Alexandria, Louisiana

  • Research Site

    Chalmette, Louisiana

  • Research Site

    Bangor, Maine

  • Research Site

    Baltimore, Maryland

  • Research Site

    Baltimore, Maryland

  • Research Site

    Columbia, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    Haverhill, Massachusetts

  • Research Site

    Flint, Michigan

  • Research Site

    Flint, Michigan

Showing 40 of 419 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.